Serum CXCL10 and CRP Levels in Patients with Acne Vulgaris in Correlation with Disease Severity

Launched by ASSIUT UNIVERSITY · Mar 7, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two specific substances in the blood, called CXCL10 and CRP, to see how they relate to the severity of acne vulgaris, which is a common skin condition. Researchers believe that measuring these substances could help indicate how severe a person's acne is and might lead to new ways to treat inflammation associated with acne. The study will gather information about acne severity using a recognized scoring system to better understand this relationship.

To participate in the trial, individuals aged 12 to 40 years old who have been diagnosed with acne vulgaris are eligible. This includes both males and females with mild, moderate, or severe acne, as long as they are not currently taking systemic treatments like isotretinoin or antibiotics. Participants will not be selected if they have certain health conditions, such as autoimmune diseases or infections, that could influence the results. Since this trial is not yet recruiting, details about what participants can expect will be provided once it starts. Overall, this research could help improve the understanding and treatment of acne in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aged 12-40 years diagnosed with acne vulgaris.
• • 2. Both genders included.
• • 3. Patients with mild, moderate, or severe acne severity as determined by a validated scoring system (e.g., Global Acne Grading System).
• • 4. Patients not on systemic acne treatment (e.g., isotretinoin or antibiotics) or anti-inflammatory drugs.
• Exclusion Criteria:
• • 1. Patients with autoimmune diseases, systemic illnesses, acute infection or any other chronic inflammatory conditions that may affect CRP or CXCL10 levels.
• • 2. Pregnant or lactating individuals.